Company / Cash & Equivalents
Merck & Co. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$14.6B
FY2025
5-year range
$6.8B / $14.6B
FY2021-FY2025
Trend
+10.0%
vs FY2024
Sector context
#2 of 207
Health Care
What the data says
Among 207 Health Care companies, Merck & Co. is in the top 1% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $6.1B in FY2017 to $14.6B in FY2025.
Based on SEC 10-K filings.
$14.6B in FY2025 with a 5-year CAGR of +12.6%. Ranks 2nd among 207 companies in Health Care.
Improved from $6.8B to $14.6B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +4.7%
- 5-Year CAGR
- +12.6%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 207This company $14.6B Sector average $669.5M
▼
+2075.6% above sector average
Key checks
Key Insights
- 5-year CAGR of +12.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 10.0% year-over-year.
- Ranks #2 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.6B | +10.0% |
| FY2024 | $13.2B | +93.6% |
| FY2023 | $6.8B | -46.1% |
| FY2022 | $12.7B | +56.8% |
| FY2021 | $8.1B | +0.6% |
| FY2020 | $8.1B | -16.8% |
| FY2019 | $9.7B | +21.5% |
| FY2018 | $8.0B | +30.7% |
| FY2017 | $6.1B | -6.5% |
| FY2016 | $6.5B | -23.6% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026